399 results about "Biopharmaceutical" patented technology

Significant research is being done to develop and improve delivery mechanisms for biopharmaceuticals and vaccines, including pulmonary (inhalation), nasal, transdermal, and oral alternatives. Market projections indicate that the delivery of proteins and vaccines by inhalation and oral formulation has become and will continue to be increasingly important. These delivery mechanisms, to be effective, will require better stabilization of the biologicals so that they can maintain potency and effectiveness at ambient temperatures for extended periods of time. The novel Preservation by Vaporization (PBV) Technology described herein provides cost-effective and efficient industrial scale stabilization of proteins, viruses, bacteria, and other sensitive biologicals, thereby allowing a production of products that are not possible to be produced by existing methods. The suggested new PBV process comprises primary drying under vacuum from a partially frozen state (i.e. slush) at near subzero temperatures followed by stability drying at elevated temperatures (i.e., above 40 degrees Celsius). The new suggested method can be performed aseptically in unit doze format (in vials) and/or in bulk format (in trays, bags, or other containers). The drying can be performed as a continuous load process in a manifold vacuum dryer comprising a plurality (e.g., 30) of vacuum chambers attached to a condenser during the drying.

New compositions formed from the combination of an active substance with a hydrogel carrier moiety are provided. The compositions are suitable for use in high-velocity transdermal particle injection techniques. Methods of providing the new compositions are also provided. In addition, methods for administering pharmacologically active agent to a subject are provided. These methods are useful for delivering drugs, biopharmaceuticals, vaccines and diagnostics agents.

The invention provides an immunity enhancing agent, an inactivated vaccine, and a preparation method thereof. The invention relates to the field of biopharmaceutical. The immunity enhancing agent comprises 0.1-21mg/mL of monophosphoryl lipid A, 1.5-125mg/mL of muramyl dipeptide, and 0.7-4.5mg/mL of beta-glucan. The invention also provides the inactivated vaccine comprising the immunity enhancing agent, and a preparation method of the inactivated vaccine. According to the invention, the immunity enhancing agent is mixed with an inactivated antigen solution, such that a water-phase solution is obtained; and the water-phase solution is mixed with an oil-phase solution, such that the inactivated vaccine is obtained. According to the immunity enhancing agent provided by the invention, with a synergetic effect of the components, body immunity level can be improved, and immune response to antigen can be improved, such that antibody level after immunization can be increased, immune window period can be shortened, and vaccine immunization effect can be enhanced. According to the inactivated vaccine comprising the immunity enhancing agent, antibody level after immunization is high, a protection period is long, and immunization window period is short.

A sterile, closed, disposable system for formulating biopharmaceutical compositions containing multiple active agents is described herein.

The present invention relates to a particle stabilized emulsion or foam comprising at least two phases and solid particles, wherein said solid particles are starch granules and said starch granules or a portion thereof are situated at the interface between the two phases providing the particle stabilized emulsion or foam. The invention further relates to the use of said particle stabilized emulsion or foam for encapsulation of substances chosen from biopharmaceuticals, proteins, probiotics, living cells, enzymes and antibodies, sensitive food ingredients, vitamins, and lipids in food products, cosmetic products, skin creams, and pharmaceutical formulations.

The present invention relates to the field of biopharmaceuticals, and in particular to a glucagon analog for treating metabolic diseases. The structural formula is: H-X2-X3-GTFTSD-X10-SKYLD-X16-X17-AAQ-DFVQWLMN-X29-X<z> or H-S-Q-GTFTSD-Y-SKYLD-X16-X17-AAQ-DFVQWLMN-X29-Xz-NH2. The described glucagon analogue has a GLP-1/GCG/GIP triple receptor agonist activity and better enzyme resistant stabilityfor neutral endopeptidase (NEP) and dipeptidyl peptidase-4(DPP-4), and has a longer half-life in vivo and duration of action compared with natural glucagon, GLP-1 and GIP.

The invention belongs to the technical field of data processing and discloses a method for constructing a double-layer gene regulation and control network. The method comprises following steps: analyzing expression data of an important regulation and control factor miRNA in a network; selecting miRNA relevant to multiple types of cancer by means of the statistics examination method; measuring Pearson correlation among the miRNA; ordering the miRNA according to the correlation and the number of controllable cancer, screening out strongly correlated miRNA and obtaining target genes thereof and interacting relations among the target genes. The present invention discloses the mechanism of gene and miRNA involved in the regulation of biological processes such as cancer and helps to understand the relationship between genes and cancer and other complex diseases and provides reference for the development of biopharmaceuticals and targeted therapy for pan-cancer. Identifying cancer-associated miRNAs and genes can be used to elucidate the mechanisms of cooperation that are involved in the regulation of key factors that influence a variety of cancer processes, cancer risk prediction, and the development of bio-targeted drugs.

Provided are a nanoporous membrane including a support; a first separation layer with a plurality of first nano-sized pores and a first matrix; and a second separation layer having a plurality of second pores respectively corresponding to the plurality of first pores of the first separation layer and a second matrix, and formed on the first separation layer, wherein a density of the plurality of the first pores and the second pores is equal to or greater than 10¹⁰/cm², and a diameter of each of the second pores is less than that of the corresponding first pore, a process of fabricating the same, and a device for a controlled release of biopharmaceuticals including the nanoporous membrane. The device for a controlled release of biopharmaceuticals including the nanoporous membrane can release biopharmaceuticals at a constant rate for a long period of time regardless of the concentration of the biopharmaceuticals including in pharmaceuticals, and high flex and selectivity.

A freezing and thawing unit for small amounts of biopharmaceuticals and biologics. The freezing and thawing unit is reduced in scale, as compared to a corresponding commercial or large-scale process. The freezing and thawing unit can be used for testing, preservation and/or processing of small quantities of biopharmaceuticals and biologics.

The invention relates to hydrotalcite preparation with rapid efficiency and a preparation process thereof, which belong to the biopharmaceuticals field. Every 1000 hydrotalcite units of the invention comprise the following constituents: 0.45-0.55kg of hydrotalcite, 0.18-0.25kg of mannitol, 12-18g of carboxymethyl starch sodium, 8.0-15.0g of magnesium stearate, 0.5-1.0g of sodium cyclamate, 0.3-0.9ml of peppermint flavor, 0.378kg-0.462kg of pre-gelatinized starch paste (12 percent by mass specific concentration) and 0.504kg-0.616kg of pre-gelatinized starch paste (5 percent by mass specific concentration). The preparation process of the invention comprises the following steps: hydrotalcite and mannitol are prepared into super-fine powder with grain diameter of 5-15um, which are blended with carboxymethyl starch sodium, sodium cyclamate and pre-gelatinized starch paste, wet granulated, sieved by a sieve with 12-16 meshes, totally mixed, packaged or tabletted to prepare finished product of hydrotalcite preparation; the hydrotalcite preparation prepared by adopting the method of the invention has fast effectiveness, good effect with low toxicity, small side-effects, pleasant taste and high suffer compliance, which is an ideal clinical antiacid.

A new method for selecting clones and recloning mammalian cells which are of importance for the production of biopharmaceuticals, preferably hamster or mouse myeloma cells, with a high degree of automation and throughput. The invention relates to methods of depositing and replicating single cell clones of the cells in question. The invention also relates to methods of preparing proteins using cells which have been obtained and replicated by single cell deposition as well as compositions which allow the replication of single cells.

The invention discloses a processing method for intelligent hydrogel using starch nano-particles as a framework, and belongs to the technical field of nutritional and healthy foods. The intelligent hydrogel having a spatial network structure is obtained by using the transnucleosidation chain extension-sugar chain entanglement reaction of skeleton water-soluble starch nano-particles as the framework. The product is the intelligent starch-based hydrogel having the advantages of good rehydration, good biocompatibility, strong gel strength, irreversible enzymatic response, reversible pH response and carrying of multi-nutrient factors. The hydrogel can realize the protection and controlled release of food function factors, and can be applied to fields of foods, biopharmaceuticals, functional materials and the like.

The invention concerns the field of detecting and quantifying misfolded proteins/peptides. In particular the detection and quantification of misfolded proteins/peptides in body fluids, on cell surfaces of humans and mammals, the detection of misfolded proteins/peptides in reagents to be tested for scientific research and/or diagnostic use and in pharmaceutical medication or their additives and it concerns as well the removal of misfolded proteins/peptides from reagents to be tested for scientific research and/or for diagnostic purposes and from pharmaceutical medication or their additives. Furthermore the invention includes substances to identify and methods to detect bio-films, a method to examine hemocompatibility of materials and a method to optimize therapeutical products, and to provide reagents microorganisms to charge with for more reliable diagnostics and quality control of biopharmaceuticals and identification substances for the screening for preliminary stages of amyloids that can be used for technical purposes.

The invention relates to a humanized gene modification inhuman animal, in particular to an animal model expressing humanized IL-6R and/or IL-6 protein. In some examples, an inhuman animal expressing the humanized IL-6R and/or IL-6 and subjected to genetic modification also has an immunodeficiency phenotype, and/or contains more humanized cytokine of IL3, GM-CSF and the like. The invention also provides a construction method of the humanized inhuman animal containing IL-6R and/or IL-6 gene modification, and an application of the construction method to the field of biopharmaceutical.

The invention discloses a method for improving the bioactivity of an exendin fusion protein, which belongs to the technical field of biopharmaceuticals. In the method, an Exendin-4 and GLP-1 are connected in series first and then are connected with human serum albumin HSA or human immunoglobulin Fc to form the fusion protein, so as to increase the bioactivity of the exendin fusion protein. The fusion protein is expressed as: (Exendin-4-GLP-1)n-HSA, (GLP-1-Exendin-4)n-HSA, (Exendin-4-GLP-1)n-Fc or (GLP-1-Exendin-1)n-Fc, wherein the value of n ranges from 1 to 5. The fusion protein prepared by the method has higher bioactivity than a fusion protein Exendin-4-HSA or a GLP-1-HSA protein. The fusion protein of the invention can be used for preparing medicaments for treating non-insulin-dependent diabetes, various symptoms of the non-insulin-dependent diabetes and obesity.

The invention belongs to the technical field of biopharmaceuticals and relates to a method for preparing L-arginine-alpha-ketoglutarate (AAKG) from raw materials comprising L-arginine and alpha-ketoglutarate obtained by fermentation. In the method, the L-arginine and alpha-ketoglutarate in the fermentation liquor are directly used as the raw materials for AAKG rather than being used for extracting the refined crystalline products. The process mainly comprises the following technical steps: fermentation liquor pretreatment, chelation, concentration, crystallization, dissolution for decolorization, recrystallization, drying and the like. The process is characterized by comprising the following steps: pretreating the fermentation liquor with L-arginine, adding a certain amount of fermentation filtrate with alpha-ketoglutarate to the pretreated fermentation liquor to be chelated, carrying out vacuum evaporation concentration and then cooling the crystal to obtain the coarse product; and recrystallizing the coarse product by utilizing an organic solvent to obtain the high-purity product. The process has the advantages of high product purity, short flow, obvious emission reduction effect and the like, and is easy for quality control. The AAKG is mainly used as a physique enhancer and has the functions of promoting the muscles to grow and recover rapidly, promoting liver cells to absorb the nutrients and energy, maintaining normal liver functions and the like.

The invention discloses a gene synthesis of Alpha-interferon of wild boars and vector construction thereof as well as a production method of a product. A number of problems of low expression capacity, products expressed in a fusion state, products with purification tags or no fermentation technology with high density exist in the domestic recombinant strains. The invention includes a method that a codon and codon pairs, preferred by Escherichia coli, are used for synthesizing an Alpha-interferon gene of the wild boar, establishing a high-efficiency expression vector and transforming a high-efficiency expression strain as well as methods of high-density fermentation of engineering bacteria, separation and purification of inclusion bodies, the modification, the renaturation and the purification of target protein and the determination of biological activity of the expressed product. The gene synthesis, the vector construction and the production method pertain to the technical field of the production of polypeptide drugs by genetic engineering in biopharmaceuticals.

The invention relates to a preparation method of polysaccharide which is extracted from plants and usage thereof, belonging to the field of biopharmaceuticals. The preparation of polysaccharide comprises extracting total polysaccharide DIP which is extracted and separated from Duchesnea indica and has clear varicella-zoster virus activity resistance property, neutral polysaccharide neutral polysaccharide DIP1 and acidic polysaccharide DIP2 in total polysaccharide, and two major active monomer compositions polysaccharide DIP30 and polysaccharide DIP 60 in acidic polysaccharide DIP2. The raw material of Duchesnea indica has wide source range, easy regeneration, easily-operated preparation method, and high reproducibility. The polysaccharide shows significant inhibition on the varicella-zoster virus, is safe, non-toxic and stable, and is a high-quality anti-viral drug candidate.